TY - JOUR
T1 - Key implementation factors in telemedicine-delivered medications for opioid use disorder
T2 - a scoping review informed by normalisation process theory
AU - Teck, Joseph Tay Wee
AU - Zlatkute, Giedre
AU - Perez, Alberto
AU - Dritschel, Heidi
AU - Ghosh, Abhishek
AU - Potenza, Marc N.
AU - Ambekar, Atul
AU - Ekhtiari, Hamed
AU - Stein, Dan
AU - Khazaal, Yasser
AU - Arunogiri, Shalini
AU - Torrens, Marta
AU - Ferri, Marica
AU - Galea-Singer, Susanna
AU - Baldacchino, Alex
N1 - Funding Information:
This project was funded by the Scottish Government Drug Deaths Task Force and the Corra Foundation. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The views expressed are those of the authors and not of the Scottish Government Drug Deaths Task Force or the Corra Foundation.
Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/1
Y1 - 2023/1
N2 - Telemedicine could improve access to medications for opioid use disorder (MOUD). Telemedicine-delivered MOUD (TMOUD) has expanded substantially in response to the restrictions imposed by the COVID-19 pandemic on in-person clinical contact, yet this expansion has not happened consistently across all health systems and countries. This Review aims to understand key factors in TMOUD implementation that might explain variations in uptake. We did a scoping review using three English language databases for articles reporting on the implementation of TMOUD services. 57 peer-reviewed articles were identified, subjected to open coding and thematic analysis, and further interpreted through normalisation process theory (NPT). NPT was originally used to evaluate telehealth innovations and has been applied extensively to describe, assess, and develop the implementation potential of a broad range of complex health-care interventions. By categorising our findings according to the four core NPT constructs of coherence, cognitive participation, collective action, and reflexive monitoring, we aim to rationalise the current evidence base to show the workability of TMOUD in practice. We find that variations in TMOUD models in practice depend on organisations' attitudes towards risk, clinicians' tensions around giving up control over standard practices, organisation-level support in overcoming operational and technological challenges, and evaluation methods that might neglect a potential widening of the digital divide.
AB - Telemedicine could improve access to medications for opioid use disorder (MOUD). Telemedicine-delivered MOUD (TMOUD) has expanded substantially in response to the restrictions imposed by the COVID-19 pandemic on in-person clinical contact, yet this expansion has not happened consistently across all health systems and countries. This Review aims to understand key factors in TMOUD implementation that might explain variations in uptake. We did a scoping review using three English language databases for articles reporting on the implementation of TMOUD services. 57 peer-reviewed articles were identified, subjected to open coding and thematic analysis, and further interpreted through normalisation process theory (NPT). NPT was originally used to evaluate telehealth innovations and has been applied extensively to describe, assess, and develop the implementation potential of a broad range of complex health-care interventions. By categorising our findings according to the four core NPT constructs of coherence, cognitive participation, collective action, and reflexive monitoring, we aim to rationalise the current evidence base to show the workability of TMOUD in practice. We find that variations in TMOUD models in practice depend on organisations' attitudes towards risk, clinicians' tensions around giving up control over standard practices, organisation-level support in overcoming operational and technological challenges, and evaluation methods that might neglect a potential widening of the digital divide.
UR - http://www.scopus.com/inward/record.url?scp=85144586555&partnerID=8YFLogxK
U2 - 10.1016/S2215-0366(22)00374-1
DO - 10.1016/S2215-0366(22)00374-1
M3 - Review Article
C2 - 36526346
AN - SCOPUS:85144586555
SN - 2215-0366
VL - 10
SP - 50
EP - 64
JO - The Lancet Psychiatry
JF - The Lancet Psychiatry
IS - 1
ER -